Has COVID-19 impacted the injectables market?

The outbreak of COVID-19 has had a mixture of effects on the injection delivery market. For example, some patients have delayed their care for fear of going into healthcare settings for treatment and potentially contracting the disease. 

Bespak by Recipharm has developed a connectivity option for autoinjectors in a bid to meet the industry’s growing demands for connected devices.

As a result, there has been more demand for injection devices that can allow both administration and monitoring in the home environment. There are medications already geared up for self-administration for example, treatment of chronic diseases such as diabetes, Rheumatoid Arthritis, and Crohn’s disease, where prefilled safety syringes and autoinjectors are used by the patient. However, it is important that the industry further explores how patients and care givers can more closely monitor self-administered medications.  

Bespak by Recipharm has developed a connectivity option for autoinjectors in a bid to meet the industry’s growing demands for connected devices. The solution can sense and transmit data to a patient’s smartphone, such as when an injection was taken and if the injection was completed with the full dose being delivered. The connectivity module is designed to allow integration with customers’ preferred connected health systems by using an open architecture compatible with technical solutions offered by a range of providers.

Read more here, in our article with Drug Development and Delivery.